Palisade Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Palisade Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-578	Closed	-$323K	–	411
2021 Q2	$323K	Sell	578 -700	-55%	-$355K	0.01%	375
2021 Q1	$605K	Sell	1,278 -25	-2%	-$12.2K	0.01%	324
2020 Q4	$629K	Buy	1,303 +125	+11%	+$67.5K	0.02%	324
2020 Q3	$659K	Buy	+1,178	New	+$714K	0.02%	323
2020 Q2	–	Sell	-1,378	Closed	-$673K	–	408
2020 Q1	$673K	Buy	+1,378	New	+$568K	0.02%	336

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Palisade Capital Management's REGN Position: Q3 2021 in Review

Palisade Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 578 shares — an estimated $323K sold.

Palisade Capital Management first reported a position in REGN in Q1 2020 and held it in 5 quarters. The position peaked at $673K in Q1 2020. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Palisade Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Palisade Capital Management sold 578 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $323K.
Palisade Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 5 quarters.
Palisade Capital Management's Regeneron Pharmaceuticals position peaked at $673K in Q1 2020.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Palisade Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.